Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Katz

Showing results (711-720 of 749) with videos related to

Pageof 75
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2019
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancerJorge Blando, Anu Sharma, Maria Gisela Higa, et al.
Alcoholism, Clinical and Experimental Research|June 8, 2001
Mechanisms of alcoholic liver disease: cytokinesM G Neuman, D A Brenner, B Rehermann, et al.
NPJ Precision Oncology|February 3, 2024
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinomaAbdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
Cancer Research|June 18, 2026
Aerobic Exercise Activates S1PR1 Signaling in Tumor Endothelial Cells to Promote Vascular Function in Pancreatic CancerRiccardo Ballarò, Truong Lam, Sumedha Pareek, et al.
Molecular Metabolism|December 31, 2021
CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loopYihui Chen, Michela Capello, Mayrim V Rios Perez, et al.
Research Square|August 23, 2023
Impact of <i>KRAS</i> Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal AdenocarcinomaAbdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
JAMA Surgery|July 13, 2017
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal AdenocarcinomaJordan M Cloyd, Huamin Wang, Michael E Egger, et al.
Annals of Surgery|May 27, 2025
Repeat Versus Single Quadratus Lumborum Block to Reduce Opioids After Open Pancreatectomy (RESQU-BLOCK): A Randomized Clinical TrialBrittany C Fields, Jose M Soliz, Barbra Bryce Speer, et al.
The Lancet. Oncology|April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trialMaria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
The Lancet. Haematology|January 5, 2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trialRoberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Pageof 75

Showing results (711-720 of 749) with videos related to

Sort By:
Pageof 75
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2019
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancerJorge Blando, Anu Sharma, Maria Gisela Higa, et al.
Alcoholism, Clinical and Experimental Research|June 8, 2001
Mechanisms of alcoholic liver disease: cytokinesM G Neuman, D A Brenner, B Rehermann, et al.
NPJ Precision Oncology|February 3, 2024
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinomaAbdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
Cancer Research|June 18, 2026
Aerobic Exercise Activates S1PR1 Signaling in Tumor Endothelial Cells to Promote Vascular Function in Pancreatic CancerRiccardo Ballarò, Truong Lam, Sumedha Pareek, et al.
Molecular Metabolism|December 31, 2021
CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loopYihui Chen, Michela Capello, Mayrim V Rios Perez, et al.
Research Square|August 23, 2023
Impact of <i>KRAS</i> Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal AdenocarcinomaAbdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
JAMA Surgery|July 13, 2017
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal AdenocarcinomaJordan M Cloyd, Huamin Wang, Michael E Egger, et al.
Annals of Surgery|May 27, 2025
Repeat Versus Single Quadratus Lumborum Block to Reduce Opioids After Open Pancreatectomy (RESQU-BLOCK): A Randomized Clinical TrialBrittany C Fields, Jose M Soliz, Barbra Bryce Speer, et al.
The Lancet. Oncology|April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trialMaria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
The Lancet. Haematology|January 5, 2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trialRoberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Pageof 75